REGENXBIO Inc., formerly ReGenX Biosciences, LLC, is a biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s AAV gene delivery platform (its NAV technology platform) consists of exclusive rights to over 100 AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). The Company focuses on the lives of patients suffering from diseases with unmet medical needs by developing and commercializing gene therapy products administered directly into the body, or in vivo, based on its NAV technology platform. Its NAV technology platform is applied in the development of over 20 product candidates for a range of diseases, including five product candidates and approximately 20 partnered product candidates developed by its NAV technology licensees. The Company’s products candidates include RGX-501, RGX-111, RGX-121, RGX-314 and RGX-321.